HIFI α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – A study of the OVCAD consortium

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1563-1569

  Braicu, Elena Ioana ^a   Luketina, Hrvoje ^a   Richter, Rolf ^a   Castillo Tong, Dan Cacsire ^b   Lambrechts, Sandrina ^d   Mahner, Sven ^e   Concin, Nicole ^f   Mentze, Monika ^a   Zeillinger, Robert ^b,c   Vergote, Ignace ^d   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

HIF1 ; Platinum response; Predictive factors; Primary epithelial ovarian cancer; Surgical outcome; Survival

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TISSUE SECTION; TREATMENT RESPONSE;

EID: 84907195186     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S65373     Document Type: Article

References (41)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4): 765–781.
2. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40(9):1213–1223.
3. du Bois A, Floquet A, Kim J W, et al. Randomized, double-blind, Phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). In: Abstracts of the 2013 ASCO Annual Meeting; May 31–June 4, 2013; Chicago, IL, USA. Abstract 5503.
4. Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol. 2013;86(2):161–175.
5. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–953.
6. du Bois A, Marth C, Pfsterer J, et al. Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. Int J Gynecol Cancer. 2012;22(2):182–185.
7. Kehoe S, Hook J, Nankivell M, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. In: Abstracts of the 2013 ASCO Annual Meeting; May 31– June 4, 2013; Chicago, IL, USA. Abstract 5500.
8. Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer. 2010;20(8):1331–1340.
9. Gruber G, Greiner RH, Hlushchuk R, et al. Hypoxia-inducible factor 1α in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 2004;6(3):R191–R198.
10. Kurokawa T, Miyamoto M, Kato K, et al. Overexpression of hypoxia-inducible-factor 1α (HIF-1α) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer. 2003;89(6):1042–1047.
11. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1α is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res. 2005;11(3):1129–1135.
12. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, O’Byrne KJ. Hypoxia-inducible factor-1α in non-small-cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer. 2004;111(1):43–50.
13. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H. HIF1-α overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer. 2005;5:84.
14. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16(24):5928–5935.
15. Zhong H, De Marzo AM, Laughner E, et al. Over expression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59(22):5830–5835.
16. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157(2):411–421.
17. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001;7(6):1661–1668.
18. Miyazawa M, Yasuda M, Fujita M, et al. Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch Gynecol Obstet. 2009;279(6):789–796.
19. Anglesio MS, George J, Kulbe H, et al. IL6–STAT3–HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear-cell cancer. Clin Cancer Res. 2011;17(8):2538–2548.
20. Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear-cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 2010;29(12): 1741–1752.
21. Nakai H, Watanabe Y, Ueda H, Hoshiai H. Hypoxia inducible factor 1-α expression as a factor predictive of efficacy of taxane/ platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer Lett. 2007;251(1):164–167.
22. Daponte A, Ioannou M, Mylonis I, et al. Prognostic significance of hypoxia-inducible factor 1α (HIF-1α) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer. 2008;8:335.
23. Seeber LM, Horree N, Vooijs MA, et al. The role of hypoxia inducible factor-1α in gynecological cancer. Crit Rev Oncol Hematol. 2011;78(3):173–184.
24. Osada R, Horiuchi A, Kikuchi N, et al. Expression of hypoxia- inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma. Hum Pathol. 2007;38(9):1310–1320.
25. Chekerov R, Braicu I, Castillo-Tong DC, et al. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. Int J Gynecol Cancer. 2013;23(2):268–275.
26. Sehouli J, Könsgen D, Mustea A, et al. [“IMO” – intraoperative mapping of ovarian cancer]. Zentralbl Gynakol. 2003;125(3–4): 129–135. German.
27. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–423.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216.
29. Friedlander M, Butow P, Stockler M, et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009;19(Suppl 2):S44–S48.
30. Vaupel P, Kelleher DK. Blood fow and oxygenation status of prostate cancers. Adv Exp Med Biol. 2013;765:299–305.
31. Chen Y, Zhang L, Pan Y, Ren X, Hao Q. Over-expression of semaphorin4D, hypoxia-inducible factor-1α; and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. Int J Mol Sci. 2012;13(10):13264–13274.
32. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance, and hypoxia-related therapies. Cancer Treat Rev. 2003;29(4):297–307.
33. Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL. Expression and significnace of TLR4 and HIF1α in pancreatic ductal adenocarcinoma. World J Gastroenterol. 2010;16(23): 2881–2888.
34. Shi CY, Fan Y, Liu B, Lou WH. HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression. Cell Physiol Biochem. 2013;32(3):561–568.
35. Cheng JC, Klausen C, Leung PC. Hypoxia-inducible factor 1α mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett. 2013;329(2):197–206.
36. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC. Over-expression of hypoxia-inducible factor 1α in ovarian clear-cell carcinoma. Gynecol Oncol. 2007;106(2):311–317.
37. Tam KF, Chan YM, Ng TY, Wong LC, Ngan HY. Ethnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan. Int J Gynecol Cancer. 2006;16(1):135–139.
38. Nakayama K, Kanzaki A, Hata K, et al. Hypoxia-inducible factor 1α (HIF-1α) gene expression in human ovarian carcinoma. Cancer Lett. 2002;176(2):215–223.
39. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small-cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85(6):881–890.
40. Yoshimura H, Dhar DK, Kohno H, et al. Prognostic impact of hypoxia-inducible factors 1α and 2α in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res. 2004;10(24):8554–8560.
41. Xiang L, Gilkes DM, Chaturvedi P, et al. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J Mol Med (Berl). 2014;92(2):151–164.